Population
18 patients with sporadic inclusion body myositis for proteomic analysis, and 62 sIBM patients for whole…
Comparison
Laser microdissection and mass spectrometry of… vs Intact myofibers and controls.
Design
Other
Authors
Loading...
Rare FYCO1 variants may increase sIBM susceptibility; hypothesis-generating and should not yet alter clinical practice or testing.
Proteomic and genomic analysis identifies FYCO1 accumulation and rare missense variants as a novel risk factor and potential pathogenic mechanism in sporadic inclusion body myositis.
Güttsches et al. (2016) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: